报价延迟最少15分钟:2026/04/23 02:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.39 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-17.85/-9.87
|
|
企业价值
29.72M
|
| 资产负债 |
|
每股账面净值
13.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.70M
|
|
每股收益
3.53
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
